Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study.

Annals of surgical oncology - 1 Sept 2023

Yang Libo, Liu Yuqiong, Han DanDan, Fu Sha, Guo Shuangping, Bao Longlong, Shi Yi, Huang Rongfang, Wan Huan, Li Wencai, Wang Zhe, Zhou Xiaoyan, Chen Gang, Liu Yueping, Ye Feng

Abstract excerpt

BACKGROUND: The objective of this work is to reveal differences in clinical and genetic features, as well as neoadjuvant chemotherapy (NAC) response, between HER2-low and HER2-zero or HER2-positive breast cancers. PATIENTS AND METHODS: A total of 245 female patients with breast cancer were retrospectively enrolled from seven hospitals. Core needle biopsy (CNB) samples were collected before NAC and used for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 37000356
DOI: 10.1245/s10434-023-13311-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study.PMID 37000356Read ↗

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysisSemantic proximity Read ↗

Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.Semantic proximity Read ↗

Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.Semantic proximity Read ↗

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.Semantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status.Semantic proximity Read ↗

Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype.Semantic proximity Read ↗

Genomic Alterations of Tumors in HER2-Low Breast Cancers.Semantic proximity Read ↗

Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.Semantic proximity Read ↗

Triple Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant ChemotherapySemantic proximity Read ↗

The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 statusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.